When it comes to Gilead Sciences (GILD), recent focus has landed squarely on its potential COVID-19 treatment, remdesivir, but now, it’s grabbing headlines for an entirely different reason.On Sunday, Bloomberg reported in an unconfirmed article that AstraZeneca (AZN) informally approached Gilead to discuss the possibility of a merger. It should be noted that currently, formal talks are not ongoing.Writing for RBC Capital, 5-star analyst Brian Abrahams tells clients that the market caps of GILD and AZN, which land at $96.6 billion and $138 billion, respectively, could make the transaction “one of the largest in recent memory.” He added, “Recall in …read more
Source:: Yahoo Finance
